NiaudetPGublerMC.WT1 and glomerular diseases. Pediatr Nephrol. 2006;21(11):1653-1660. doi:10.1007/s00467-006-0208-1.
3.
Gariépy-AssalLGilbertRDŽiaugraAFosterBJ.Management of Denys-Drash syndrome: a case series based on an international survey. Clin Nephrol Case Stud. 2018;6(01):36-44. doi:10.5414/CNCS109515.
4.
LipskaBSRanchinBIatropoulosP, et al. Genotype-phenotype associations in WT1 glomerulopathy. Kidney Int. 2014;85(5):1169-1178. doi:10.1038/ki.2013.519.
5.
WhitePCSpeiserPW.Congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Endocr Rev. 2000;21(3):245-291. doi:10.1210/edrv.21.3.0398.
6.
LadjouzeADonaldsonMPlottonI, et al. Genotype, mortality, morbidity, and outcomes of 3β-hydroxysteroid dehydrogenase deficiency in Algeria. Front Endocrinol (Lausanne). 2022;13:867073. doi:10.3389/fendo.2022.867073.
7.
SpeiserPWChawlaRChenM, et al. Newborn screening protocols and positive predictive value for congenital adrenal hyperplasia vary across the United States. Int J Neonatal Screen. 2020;6(2):37. doi:10.3390/ijns6020037.
8.
SpeiserPWArltWAuchusRJ, et al. Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2018;103(11):4043-4088. doi:10.1210/jc.2018-01865.
